Gemcitabine

Drug Profile

Gemcitabine

Alternative Names: dFdC; dFdCTP; Gemtro; Gemzar; LY 188011

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Eli Lilly; Genentech; University of Innsbruck
  • Developer Eli Lilly; Mayo Clinic; National Cancer Institute (USA)
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Phase II Lymphoma; Renal cell carcinoma; Salivary gland cancer
  • Phase I Head and neck cancer; Solid tumours

Most Recent Events

  • 16 Feb 2017 Chonnam National University Hospital and Bayer plan a phase I/II trial for Peripheral T-cell or NK/T-cell lymphoma in South Korea (NCT03052933)
  • 01 May 2016 Eli Lilly completes a phase II trial in Renal cell carcinoma (Combination therapy, Metastatic disease) in USA (IV-infusion) (NCT00496587)
  • 30 May 2015 Gemcitabine is still in phase II trials for Renal cell carcinoma (Combination therapy, Metastatic disease) in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top